Discovery and validation of biomarkers to support clinical development of NXP800: A first-in-class orally active, small-molecule HSF1 pathway inhibitor. (October 2022) - Workman, P.; Clarke, P.A.; Te Poele, R.; Powers, M.; Box, G.; De Billy, E.; De Haven Brandon, A.; Hallsworth, A.; Hayes, A.; McCann, H.; Sharp, S.; Valenti, M.; et al.